Early test of potential HIV Game-Changer begins
NCT ID NCT06012136
Summary
This early-stage study is testing the safety of new long-acting HIV drugs called capsid inhibitors in healthy volunteers. Researchers will give single injections to 85 participants and carefully monitor for side effects, particularly at the injection site. The main goal is to understand how safe these experimental drugs are and how they move through the body before testing them in people with HIV.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Las Vegas, Nevada, 89113, United States
-
GSK Investigational Site
Austin, Texas, 78744, United States
Conditions
Explore the condition pages connected to this study.